Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Evaluation of Early Oral Estramustine, Oral Etoposide and Intravenous Paclitaxel in Combination With Hormone Therapy in Patients With High-Risk Metastatic Adenocarinoma of the Prostate

NCT00028769 is registered in ClinicalTrials.gov with SWOG Cancer Research Network as lead sponsor.

NCT NCT00028769
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00028769 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Evaluation of Early Oral Estramustine, Oral Etoposide and Intravenous Paclitaxel in Combination With Hormone Therapy in Patients With High-Risk Metastatic Adenocarinoma of the Prostate
Lead sponsor
SWOG Cancer Research Network
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2001
Completion date
July 31, 2011
Enrollment
41 (actual)
Sites
91

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer